Cargando…

First-line treatment of women with advanced ovarian cancer: focus on bevacizumab

Ovarian cancer is the fifth most common cause of cancer death in women in Europe. Despite the progress, almost 70% of the patients relapse. The standard treatment is cytoreductive surgery followed by platinumtaxane chemotherapy; in patients with a disseminated disease, one option is neoadjuvant chem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchetti, Claudia, Muzii, Ludovico, Romito, Alessia, Benedetti Panici, Pierluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371937/ https://www.ncbi.nlm.nih.gov/pubmed/30799939 http://dx.doi.org/10.2147/OTT.S155425

Ejemplares similares

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials
por: Marchetti, Claudia, et al.
Publicado: (2015)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
por: De Felice, Francesca, et al.
Publicado: (2015)

Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis
por: Marchetti, Claudia, et al.
Publicado: (2016)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer
por: Marchetti, Claudia, et al.
Publicado: (2018)

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers
por: Marchetti, Claudia, et al.
Publicado: (2014)

Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis
por: Caruso, Giuseppe, et al.
Publicado: (2022)

Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
por: Marchetti, Claudia, et al.
Publicado: (2014)

Pelvic Inflammatory Disease: Possible Catches and Correct Management in Young Women
por: Di Tucci, Chiara, et al.
Publicado: (2018)

Fertility preservation in ovarian tumours
por: Tomao, Federica, et al.
Publicado: (2018)

Comparison of Anogenital Distance and Correlation with Vulvo-vaginal Atrophy: A Pilot Study on Premenopausal and Postmenopausal Women
por: Domenici, Lavinia, et al.
Publicado: (2018)

Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
por: Di Donato, Violante, et al.
Publicado: (2020)

Fertility preservation in gynaecologic cancers
por: De Felice, Francesca, et al.
Publicado: (2018)

Cabergoline as an adjuvant to standard heart failure treatment in peripartum cardiomyopathy: A case report and review of the literature
por: Caruso, Giuseppe, et al.
Publicado: (2020)

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
por: Conic, Irena, et al.
Publicado: (2022)

First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
por: Tomao, Federica, et al.
Publicado: (2020)

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
por: Palaia, Innocenza, et al.
Publicado: (2020)

First line targeted therapies in breast cancer: focus on bevacizumab
por: Milano, Amalia, et al.
Publicado: (2007)

Immunotherapy in endometrial cancer: new scenarios on the horizon
por: Di Tucci, Chiara, et al.
Publicado: (2019)

Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis
por: Di Donato, Violante, et al.
Publicado: (2021)

An Unexpected Complete Remission of Advanced Intestinal-Type Vulvar Adenocarcinoma after Neoadjuvant Chemotherapy: A Case Report and a Literature Review
por: Musella, Angela, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?
por: Gasparri, Maria Luisa, et al.
Publicado: (2017)

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets
por: Napoletano, Chiara, et al.
Publicado: (2019)

Fertility-sparing surgery for women with stage I cervical cancer of 4 cm or larger: a systematic review
por: Di Donato, Violante, et al.
Publicado: (2021)

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Heterogeneity Among Poor Ovarian Responders According to Bologna Criteria Results in Diverging Cumulative Live Birth Rates
por: Romito, Alessia, et al.
Publicado: (2020)

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
por: Rossi, Luigi, et al.
Publicado: (2013)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Update on first-line treatment of advanced ovarian carcinoma
por: Kemp, Z, et al.
Publicado: (2013)

Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
por: Napoletano, Chiara, et al.
Publicado: (2010)

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
por: Neyt, Mattias, et al.
Publicado: (2018)

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
por: Cervantes, A., et al.
Publicado: (2023)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Is CA72-4 a Useful Biomarker in Differential Diagnosis between Ovarian Endometrioma and Epithelial Ovarian Cancer?
por: Anastasi, Emanuela, et al.
Publicado: (2013)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Intraoperative Three-Dimensional Transvaginal Ultrasound for Hysteroscopic Metroplasty: a Controlled Study
por: Muzii, Ludovico, et al.
Publicado: (2023)

First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer
por: Roy, Somnath, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_16hcglasisgiak5q42ibkb65ru